ChiCTR-IIR-17013561: To evaluate the tolerability, pharmacokinetics, pharmacodynamics of TQ-F3083 capsules in single-center, randomized, double-blind, placebo-controlled multi-dose, single, multiple administrations in healthy subjects |
|
|
| Recruiting | 1 | 70 | | The first group needed to complete a single-dose clinical study at a dose of 2 mg and 10 subjects, 8 of whom received the test drug and 2 received placebo, with a similar male-to-female ratio. Administered once, administered under fasting conditions, and tolerated at D4. ;A second set of tests was performed on the first set of tolerability evaluations. The second group needed to complete a single-dose clinical study at a dose of 5 mg with 10 subjects, 8 of whom received the test drug and 2 received placebo, with a similar male-to-female ratio. Administered once, ;The third set of tests was conducted with the second set of tolerability evaluable as tolerated. The third group needed to complete a single-dose clinical study at a dose of 10 mg with 10 subjects, 8 of whom received the investigational drug, 2 received placebo, and the ratio of men and women ;A fourth set of tests was conducted with the third set of tolerability evaluable as tolerated. The fourth group dose of 20mg, need to complete a single administration, the impact of food on pharmacokinetics, multiple clinical trials and drug metabolism research, a total of 18 subjects, A group of 10 ;The fifth set of tests was conducted with the fourth set of tolerability evaluable as tolerated. The fifth group needed to complete a single-dose clinical study at a dose of 40 mg with 10 subjects, 8 of whom received the test drug and 2 received placebo, with a similar male-to-female ratio. Admi ;A sixth set of tests was conducted with the fifth set of tolerability evaluable as tolerated. The sixth group needed to complete a single-dose clinical study at a dose of 40 mg in 10 subjects, 8 of whom received the test drug and 2 received placebo, with a similar male-to-female ratio. Administe ;First selected 2 subjects participated in the 2mg TQ-F3083 single-dose pre-trial clinical study | The First Hospital of Jilin University; Chia Tai Tianqing Pharmaceutical Group Co, Ltd, Chia Tai Tianqing Pharmaceutical Group Co,Ltd | Diabetes | | | | |
ChiCTR2000032251: CT-707 versus crizotinib in advanced ALK positive non-small-cell lung cancer: a multi-center, randomized, open-lable, phase III study |
|
|
| Recruiting | 3 | 414 | | CT-707 ;Crizotinib | Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Shouyao Holdings (Beijing) Co.Ltd., Major science and technology special project of Ministry of Science and Technology of the People's Republic of China | Non-small-cell lung cancer | | | | |
NCT05580445: Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 114 | RoW | CT-707, CT-707 granules, Toripalimab, Toripalimab injection, Gemcitabine, GEMZAR | Shouyao Holdings (Beijing) Co. LTD | Advanced Pancreatic Cancer | 08/24 | 08/24 | | |
